Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

SIMPLE SUMMARY: The urgency of the COVID-19 pandemic has led to accelerated vaccine development within less than a year. Emerging data suggest that the ability of patients with hematological malignancies to form an adequate number of antibodies in response to vaccination for SARS-CoV-2 is suboptimal...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Gavriatopoulou, Maria, Fotiou, Despina, Giatra, Chara, Asimakopoulos, Ioannis, Dimou, Maria, Sklirou, Aimilia D., Ntanasis-Stathopoulos, Ioannis, Darmani, Ismini, Briasoulis, Alexandros, Kastritis, Efstathios, Angelopoulou, Maria, Baltadakis, Ioannis, Panayiotidis, Panayiotis, Trougakos, Ioannis P., Vassilakopoulos, Theodoros P., Pagoni, Maria, Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430746/
https://www.ncbi.nlm.nih.gov/pubmed/34503290
http://dx.doi.org/10.3390/cancers13174480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430746/
https://www.ncbi.nlm.nih.gov/pubmed/34503290
http://dx.doi.org/10.3390/cancers13174480

Ejemplares similares